Citadel Advisors LLC Boosts Stock Position in Chemed Co. (NYSE:CHE)

Share on StockTwits

Citadel Advisors LLC increased its stake in Chemed Co. (NYSE:CHE) by 542.3% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 98,213 shares of the company’s stock after buying an additional 82,921 shares during the period. Citadel Advisors LLC owned 0.62% of Chemed worth $35,439,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Krane Funds Advisors LLC purchased a new stake in shares of Chemed in the 2nd quarter worth approximately $26,000. Bremer Bank National Association purchased a new stake in shares of Chemed in the 1st quarter worth approximately $29,000. Advisory Services Network LLC grew its stake in shares of Chemed by 117.9% in the 2nd quarter. Advisory Services Network LLC now owns 85 shares of the company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Icon Wealth Partners LLC purchased a new stake in shares of Chemed in the 1st quarter worth approximately $61,000. Finally, Steward Partners Investment Advisory LLC purchased a new stake in shares of Chemed in the 2nd quarter worth approximately $92,000. Institutional investors own 87.12% of the company’s stock.

In other news, Director Walter L. Krebs sold 2,910 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $430.41, for a total value of $1,252,493.10. Following the completion of the sale, the director now directly owns 9,318 shares in the company, valued at approximately $4,010,560.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald E. Saunders sold 400 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $432.87, for a total value of $173,148.00. Following the completion of the sale, the director now owns 7,408 shares of the company’s stock, valued at $3,206,700.96. The disclosure for this sale can be found here. Insiders have sold a total of 46,812 shares of company stock worth $20,005,507 over the last three months. Insiders own 3.96% of the company’s stock.

CHE stock traded up $1.06 during midday trading on Friday, hitting $426.32. The company’s stock had a trading volume of 96,598 shares, compared to its average volume of 111,213. The company has a market cap of $6.74 billion, a PE ratio of 35.74, a P/E/G ratio of 2.88 and a beta of 1.13. Chemed Co. has a 12 month low of $260.03 and a 12 month high of $441.79. The company has a current ratio of 0.81, a quick ratio of 0.78 and a debt-to-equity ratio of 0.25. The firm’s 50-day moving average is $425.92 and its 200-day moving average is $362.31.

Chemed (NYSE:CHE) last released its quarterly earnings results on Thursday, July 25th. The company reported $3.36 earnings per share for the quarter, beating the consensus estimate of $3.09 by $0.27. The firm had revenue of $473.60 million for the quarter, compared to analysts’ expectations of $471.72 million. Chemed had a return on equity of 35.63% and a net margin of 10.94%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.81 EPS. Analysts expect that Chemed Co. will post 13.54 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Monday, August 12th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.30%. This is a boost from Chemed’s previous quarterly dividend of $0.30. The ex-dividend date was Friday, August 9th. Chemed’s dividend payout ratio is presently 10.73%.

Several equities analysts recently issued reports on CHE shares. ValuEngine raised Chemed from a “hold” rating to a “buy” rating in a research report on Friday, June 7th. Bank of America upped their price objective on Chemed from $470.00 to $500.00 and gave the company a “buy” rating in a research report on Friday, September 6th. Oppenheimer upped their price objective on Chemed from $400.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada upped their price objective on Chemed to $405.00 and gave the company a “sector perform” rating in a research report on Monday, July 29th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $411.25.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.

Read More: How the Consumer Price Index (CPI) is calculated?

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report